Global Biopsy Devices Market Overview:
Biopsy Device is an equipment used to remove the tissue from any particular part of the body and examine it for the disease. Surging demand and growing awareness regarding breast cancer treatment and diagnosis are propelling the market for Biopsy Device. Biopsy Device is expected to grow in the forecasted period owing to the growing prevalence of cancer and rapid change in environmental condition and rising population.
As per latest study released by AMA Research, the Global Biopsy Devices market is expected to see growth rate of 5.83% and may see market size of USD2.47 Billion by 2030.
Attributes | Details |
---|
Study Period | 2018-2030 |
Base Year | 2023 |
Forecast Period | 2024-2030 |
Historical Period | 2018-2023 |
Unit | Value (USD Billion) |
Customization Scope | Avail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility |
Influencing Trend:
Development of Fully Integrated Biopsy Devices and Emergence of Liquid Biopsy
Market Growth Drivers:
Increasing Demand for Minimally Invasive Surgeries and Growing Prevalence of Lung Cancer
Challenges:
Underdeveloped Healthcare Infrastructure and Dearth of Resources in Developing Countries
Restraints:
Risk of rising Infection and High Price Associated With Biopsy Devices
Opportunities:
Rising Population and Growing Prevalence of Cancer and Untapped Rural Market
Competitive Landscape:
Some of the key players profiled in the report are C. R. Bard, Inc. (United States), Becton, Dickinson and Company (United States), Cook Group Incorporated (United States), Devicor Medical Products, Inc., (Leica Biosystems) (Germany), Argon Medical Devices (United States), B. Braun Melsungen AG (Germany), Cardinal Health, Inc. (United States), Olympus Corporation (Japan) and Boston Scientific Corporation (United States). Additionally, following companies can also be profiled that are part of our coverage like FUJIFILM Holdings Corporation (Japan), INRAD, Inc. (United States) and Medtronic plc (Ireland). Analyst at AMA Research see United States Players to retain maximum share of Global Biopsy Devices market by 2030. Considering Market by Guidance Technique, the sub-segment i.e. Ultrasound-guided Biopsy will boost the Biopsy Devices market. Considering Market by End User, the sub-segment i.e. Hospitals will boost the Biopsy Devices market.
According to statistics published by WHO, cancer has become one of the leading causes of death worldwide. The global incidence of cancer in 2012 was 14.1 million and it is awaited to rise by 70.0% over the next two decades.
What Can be Explored with the Biopsy Devices Market Study
Gain Market Understanding
Identify Growth Opportunities
Analyze and Measure the Global Biopsy Devices Market by Identifying Investment across various Industry Verticals
Understand the Trends that will drive Future Changes in Biopsy Devices
Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals
Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Biopsy Devices market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Biopsy Devices market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Biopsy Device Manufacturers, Suppliers and Distributors of Biopsy Devices, Research Institutes and Academic Centers, Hospitals, Oncology Centers, Health Insurance Payers, Regulatory Authorities and Venture Capitalists.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.